Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
a study on Hematopoietic Cell Transplantation Leukemia Solid Tumor
Summary
- Location
- at UC Davis UCLA UCSF
- Dates
- study started
- Principal Investigator
- by Satiro De Oliveira, MD (ucla)

Description
Summary
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Official Title
Umbrella Long-Term Follow-Up Protocol
Details
PRIMARY OBJECTIVES:
- To develop a mechanism for tracking and retaining patients enrolled on Children's Oncology Group (COG) protocols.
II. To maintain regular, lifetime contact with patients in order to obtain current identification and contact information, and self/parent-reported quality of life and health status.
III. To locate patients who are lost-to-follow-up for COG (or Legacy Group) protocols targeted for follow-up by the Long-Term Follow-Up Center (LTFC).
IV. To provide current patient contact information and self/parent-reported health status updates to the COG Statistics and Data Center (SDC) and to each patient's COG institution.
- To facilitate collection of protocol-specific outcome data through collaboration with the LTFC Oversight Committee, the SDC, and the member institutions.
OUTLINE: This is an umbrella protocol for all long-term follow-up at COG institutions.
Within 3 months of enrollment on ALTE05N1, patients receive a packet introducing the Long-Term Follow-Up Center (LTFC). Patients are asked to complete a patient response form, verify information provided in packet, and update contact and health status information. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients may respond by use of postage prepaid envelopes, secure online form, or 24-hour toll-free telephone number. After initial contact, the LTFC will contact the patient annually.
Keywords
Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor, Assessment of Therapy Complications
Eligibility
Inclusion Criteria:
- The patient must reside in the U.S. on the date of enrollment to ALTE05N1
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Locations
- Mattel Children's Hospital UCLA
accepting new patients
Los Angeles California 90095 United States - University of California Davis Comprehensive Cancer Center
accepting new patients
Sacramento California 95817 United States - UCSF Medical Center-Parnassus
in progress, not accepting new patients
San Francisco California 94143 United States - UCSF Medical Center-Mission Bay
accepting new patients
San Francisco California 94158 United States - Cedars Sinai Medical Center
accepting new patients
Los Angeles California 90048 United States - Rady Children's Hospital - San Diego
accepting new patients
San Diego California 92123 United States - Children's Hospital Los Angeles
accepting new patients
Los Angeles California 90027 United States - Children's Hospital of Orange County
accepting new patients
Orange California 92868 United States - Kaiser Permanente-Oakland
accepting new patients
Oakland California 94611 United States - Valley Children's Hospital
accepting new patients
Madera California 93636 United States
Lead Scientist at University of California Health
- Satiro De Oliveira, MD (ucla)
Details
- Status
- accepting new patients
- Start Date
- Sponsor
- Children's Oncology Group
- ID
- NCT00736749
- Study Type
- Observational
- Participants
- Expecting 5000 study participants
- Last Updated